The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma

Abstract

PurposeTo evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC).Materials and MethodsBetween March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1–14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed.ResultsUntil January 2014, the median follow-up time was 13 months (range, 4–41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3–5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22).ConclusionsEndostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

“…Endostar, a novel modified recombinant human endostatin, has showed strong antiangiogenic effect on various xenograft tumor model and cancer patients, including NPC. [32][33][34] The results of this study demonstrated that Endostar impeded tumor growth without evident tumor regression and that a significant tumor growth inhibition was not observed until day 8, because Endostar was principally cytostatic rather than cytotoxic. It was also shown that Endostar could reduce the tumor vessels, resulting in the decrease of microvessel density, and subsequently lowered the integrin avβ3 expression.…”

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

“…Twenty-two patients with locally advanced recurrent nasopharyngeal carcinoma (rIII-IVb) were enrolled in a study of rh-endostatin combined with radiochemotherapy [38]. Patients received IMRT treatment, platinum-based adjuvant therapy and IV injection of rh-endostatin at 105 mg/m 2 , continuously for 14 days, in a 21-day treatment cycle.…”

Extracellular Matrix, a Hard Player in Angiogenesis

“…The fragment also inhibits FGF-2 and VEGF-induced EC proliferation and migration [86,87]. Relying on its anti-angiogenic properties, endostatin displays potent anti-tumoral effects [88,89,90,91]. Remarkably, the treatment with the recombinant fragment induces vessel normalization and, as a consequence an improved chemotherapy efficacy [92].…”

“…Remarkably, the treatment with the recombinant fragment induces vessel normalization and, as a consequence an improved chemotherapy efficacy [92]. Clinical trials have also been attempted with seesawing results: some deluded the expectations [93,94], whereas others demonstrated a potential benefit [91,95]. It is possible that this may depend on the tumor type and the quality of the vasculature characterizing each tumor.…”